Andreas Wollenberg
0000-0003-0177-8722
Publication & Citation Trends
Publications
0 total
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND
Cited by 0
Semantic Scholar
The Atopic Dermatitis Shared Decision-Making Tool: Implementing the AHEAD Approach in Clinical Practice
Cited by 0
Semantic Scholar
Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 Trial
Cited by 0
Semantic Scholar
Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension Study
Cited by 0
Semantic Scholar
117: Long-term efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis
Cited by 0
Semantic Scholar
Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis.
Cited by 0
Semantic Scholar
Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities.
Cited by 1
Semantic Scholar
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis
Cited by 9
Semantic Scholar
Research Topics
Dermatology and Skin Diseases
(397)
Allergic Rhinitis and Sensitization
(159)
Asthma and respiratory diseases
(108)
Food Allergy and Anaphylaxis Research
(105)
Psoriasis: Treatment and Pathogenesis
(90)
Affiliations
Augsburg University
Oxfam
Hudson Institute
Vrije Universiteit Brussel
University of Augsburg